To Assess The Performance And Tolerance Of Janesse 20 In The Volume Restoration Of Labia Majora

Inclusion Criteria: * Women with age ≥ 18. * Women seeking genital rejuvenation with Genital Appearance Satisfaction Scale (GAS) \>20 and Cosmetic Procedure Screening Scale modified for Labia (COPS-L)\>40 . * Patients with diagnosis of Body Dysmorphic Disorder (BDD) following DSM-IV criteria or congenital or post-menopausal Labia Majora hypotrophy * • The Labia Majora (left and right) width and/or length must be between the 5th and 95th percentiles as reported in the Annex 4 of the protocol (modified table from Kreklau A e t al 2018). The measurement must be performed by the Investigators using the Sliding Zuricher Caliper mm130. * Women willing to provide signed informed consent to clinical investigation participation. Exclusion Criteria: * Use of aspirin and antiplatelet agents a week prior to treatment. * Pregnant or lactating women. * Women with history of allergy or hypersensitivity to the HA or to other ingredients of the dermal filler. * Women with history of allergy or hypersensitivity to Lidocaine, Mepivacaine or Prilocaine or local anaesthetics. * Women with any dermal systemic pathologies, such as systemic lupus erythematosus, psoriasis, scleroderma etc. * Women presenting bleeding disorders in the past or present. * Women taking or having indications for anticoagulant therapy. * Use of concomitant treatments or procedures aimed to improve genital skin rejuvenation over the last six months before the clinical investigation enrolment, such as chemical peeling, dermabrasion, laser resurfacing. * Women suffering from infectious diseases including herpes simplex virus infection, active hepatitis, Human Papilloma Virus (HPV) or Human Immunodeficiency Virus (HIV). * Women suffering from local dermatitis (vulvar scaly papilloma, mycosis, bacterial infection near the injection area). * Women at risk in term of precautions, warnings and contra-indications referred in the package insert of the clinical investigation device. * Women with autoimmune diseases, streptococcus disease. * Women with any active irritation or inflammation in the target areas of injection. * Recent vulvae surgery in the treatment area or progressive recent or nearby cancers (i.e. cervical cancer). * Tachycardia or other severe heart rhythm disorders * Women with previous regional radiotherapy. * Women who practice cycling or dedicate themselves to horse riding; women who practice bodybuilding or who perform professional sports. * Women unlikely to cooperate in the clinical investigation or to comply with the treatment or with the clinical investigation visits. * Performed dentist visit in the last week. * Women participating in another clinical investigation or treated with another HA filler with the same indications at the same time or within the preceding 30 days.